Balyasny Asset Management’s ImmunityBio IBRX Stock Holding History

Balyasny Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$732K	Sell	83,584 -20,287	-20%	-$154K	﹤0.01%	2365
2026 Q1	$797K	Buy	103,871 +52,231	+101%	+$358K	﹤0.01%	2170
2025 Q4	$102K	Buy	51,640 +33,914	+191%	+$76.8K	﹤0.01%	2954
2025 Q3	$43.6K	Buy	+17,726	New	+$45.6K	﹤0.01%	2827
2025 Q2	–	Sell	-56,165	Closed	-$169K	–	3063
2025 Q1	$169K	Buy	+56,165	New	+$170K	﹤0.01%	2620
2024 Q4	–	Sell	-65,811	Closed	-$245K	–	2978
2024 Q3	$245K	Sell	65,811 -141,385	-68%	-$654K	﹤0.01%	2508
2024 Q2	$1.31M	Buy	+207,196	New	+$1.37M	﹤0.01%	1692
2023 Q3	–	Sell	-193,285	Closed	-$537K	–	2475
2023 Q2	$537K	Buy	193,285 +121,019	+167%	+$342K	﹤0.01%	1834
2023 Q1	$132K	Sell	72,266 -824,695	-92%	-$2.56M	﹤0.01%	2290
2022 Q4	$4.55M	Buy	896,961 +849,054	+1,772%	+$4.66M	0.01%	1073
2022 Q3	$238K	Sell	47,907 -17,038	-26%	-$77.6K	﹤0.01%	2266
2022 Q2	$242K	Buy	+64,945	New	+$261K	﹤0.01%	2158
2018 Q2	–	Sell	-11,189	Closed	-$44K	–	1938
2018 Q1	$44K	Buy	+11,189	New	+$49.1K	﹤0.01%	1864
2017 Q3	–	Sell	-50,000	Closed	-$380K	–	1973
2017 Q2	$380K	Buy	+50,000	New	+$216K	﹤0.01%	1268

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management's IBRX Position: Q2 2026 in Review

Balyasny Asset Management reduced its ImmunityBio (IBRX) stake by 20% in Q2 2026, selling an estimated $154K and leaving 83,584 shares worth $732K. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

Balyasny Asset Management first reported a position in IBRX in Q2 2017 and has held it in 14 quarters since. The position peaked at $4.55M in Q4 2022. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Balyasny Asset Management held 83,584 shares of ImmunityBio worth $732K as of Q2 2026.
Balyasny Asset Management sold 20,287 ImmunityBio shares in Q2 2026, an estimated $154K.
ImmunityBio made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2365 holding.
Balyasny Asset Management first reported a position in ImmunityBio in Q2 2017 and has held it in 14 quarters since.
Balyasny Asset Management's ImmunityBio position peaked at $4.55M in Q4 2022.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.